Abstract
Both competitive (e.g. AP5, AP7, CPP, CGS 19755, CGP 37849, CGP 39551) and non-competitive (e.g. MK 801, PCP, ketamine, tiletamine, dextrorphan, dextromethorphan and ketamine) NMDA antagonists have cerebroprotective activity in a number of ischemia, hypoxia and trauma models, as well as anticonvulsant activity in a wide range of animal seizure models. Their pharmacological efficacies, on the whole, correlate well with their affinities for the NMDA receptor.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
